Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Debt to Equity (2017 - 2021)

Sunshine Biopharma (SBFM) has disclosed Debt to Equity for 5 consecutive years, with $8.98 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Debt to Equity rose 1003.17% year-over-year to $8.98, compared with a TTM value of $8.98 through Dec 2021, up 1003.17%, and an annual FY2021 reading of $8.98, up 1003.17% over the prior year.
  • Debt to Equity was $8.98 for Q4 2021 at Sunshine Biopharma, up from -$2.73 in the prior quarter.
  • Across five years, Debt to Equity topped out at $8.98 in Q4 2021 and bottomed at -$5.57 in Q4 2018.
  • Average Debt to Equity over 5 years is -$0.6, with a median of -$0.82 recorded in 2020.
  • The sharpest move saw Debt to Equity tumbled 3908.81% in 2018, then skyrocketed 1003.17% in 2021.
  • Year by year, Debt to Equity stood at -$0.14 in 2017, then plummeted by 3908.81% to -$5.57 in 2018, then skyrocketed by 99.33% to -$0.04 in 2019, then plummeted by 2580.8% to -$0.99 in 2020, then skyrocketed by 1003.17% to $8.98 in 2021.
  • Business Quant data shows Debt to Equity for SBFM at $8.98 in Q4 2021, -$2.73 in Q3 2021, and -$2.35 in Q2 2021.